| Literature DB >> 34276997 |
Aron Gortman1, Noel J Aherne1,2,3, Justin Westhuyzen1, Julan V Amalaseelan4, Patrick M Dwyer4, Matthew Hoffmann5, Andrew T Last5, Thomas P Shakespeare1,2.
Abstract
Metaplastic breast carcinoma is an uncommon subtype of invasive ductal carcinoma with a tendency towards poorer clinical outcomes. Following ethical approval, the current study reviewed the institutional records of ~2,500 women with breast cancer. A total of 14 cases of metaplastic breast cancer were reviewed for management and treatment outcomes. The results demonstrated that patients had median follow up of 30 months, a 5-year disease-free survival of 57.1% and 5-year overall survival of 57.1%. The majority of patients had at least T2 disease and all tumours were high grade. Additionally, most patients were triple negative and nodal metastases were uncommon. Metaplastic breast cancer is an aggressive variant of invasive breast cancer. Most patients can be treated with breast conservation and survival parameters tend to be worse than more common breast cancer subtypes.Entities:
Keywords: breast cancer; metaplastic; radiation; triple negative
Year: 2021 PMID: 34276997 PMCID: PMC8278413 DOI: 10.3892/mco.2021.2340
Source DB: PubMed Journal: Mol Clin Oncol ISSN: 2049-9450